Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer

There is a continuing debate about the proportion of cancer patients that benefit from precision oncology, attributable in part to conflicting views as to which molecular alterations are clinically actionable. To quantify the expansion of clinical actionability since 2017, we annotated 47,271 solid...

Full description

Saved in:
Bibliographic Details
Published in:Cancer discovery 2024-01, Vol.14 (1), p.49-65
Main Authors: Suehnholz, Sarah P, Nissan, Moriah H, Zhang, Hongxin, Kundra, Ritika, Nandakumar, Subhiksha, Lu, Calvin, Carrero, Stephanie, Dhaneshwar, Amanda, Fernandez, Nicole, Xu, Benjamin W, Arcila, Maria E, Zehir, Ahmet, Syed, Aijazuddin, Brannon, A Rose, Rudolph, Julia E, Paraiso, Eder, Sabbatini, Paul J, Levine, Ross L, Dogan, Ahmet, Gao, Jianjiong, Ladanyi, Marc, Drilon, Alexander, Berger, Michael F, Solit, David B, Schultz, Nikolaus, Chakravarty, Debyani
Format: Article
Language:English
Subjects:
Humans
Medical Oncology - methods
Mutation
Neoplasms - therapy
Precision Medicine - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There is a continuing debate about the proportion of cancer patients that benefit from precision oncology, attributable in part to conflicting views as to which molecular alterations are clinically actionable. To quantify the expansion of clinical actionability since 2017, we annotated 47,271 solid tumors sequenced with the MSK-IMPACT clinical assay using two temporally distinct versions of the OncoKB knowledge base deployed 5 years apart. Between 2017 and 2022, we observed an increase from 8.9% to 31.6% in the fraction of tumors harboring a standard care (level 1 or 2) predictive biomarker of therapy response and an almost halving of tumors carrying nonactionable drivers (44.2% to 22.8%). In tumors with limited or no clinical actionability, TP53 (43.2%), KRAS (19.2%), and CDKN2A (12.2%) were the most frequently altered genes. Although clear progress has been made in expanding the availability of precision oncology-based treatment paradigms, our results suggest a continued unmet need for innovative therapeutic strategies, particularly for cancers with currently undruggable oncogenic drivers. See related commentary by Horak and Fröhling, p. 18. This article is featured in Selected Articles from This Issue, p. 5.
ISSN:2159-8274
2159-8290
DOI:10.1158/2159-8290.CD-23-0467